ArticleCirculation reports2025
Improvement of Cardiovascular Prognostic Value of Endothelial Function Tests by Repeated Measurements.
Article in Circulation reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Coronary Microvascular Dysfunction in Hemodialysis-Dependent End-Stage Renal Disease: Prevalence, Characteristics, and Prognostic Implications.Circulation reports · 2026Article
- Peripheral microvascular function and long-term cardiovascular outcomes after percutaneous coronary intervention in patients with obstructive coronary artery disease.International journal of cardiology. Heart & vasculature · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The clinical significance of monitoring endothelial function in predicting cardiovascular events has not yet been fully explored. Methods and Results: Patients with diabetes or hypertension were enrolled in this study. Three flow-mediated dilation (FMD) and 2 EndoPAT reactive hyperemia index (RHI) were measured periodically in 3 years at 1.5-year intervals. Patients were followed up for 10 years after the examination period. In the FMD study, 136 patients were classified as those with consistently good endothelial function, as defined by FMD >7% on 3 occasions (n=33), and those without (n=103). In multivariate Cox analysis, patients who maintained high FMD had less thromboembolic major cardiovascular events or angina pectoris (n=24; hazard ratio [HR] 0.216; 95% confidence interval [CI] 0.047-0.985; P=0.048). In the EndoPAT study, 120 patients were classified as those with consistently abnormal endothelial function, as defined by RHI <1.67 on 2 occasions (n=34), and those without (n=86). There were 9 all-cause deaths and 10 hospitalizations for heart failure. Patients with consistent RHI <1.67 had a higher mortality (HR 10.794; 95% CI 1.520-76.629; P=0.017) and incidence of heart failure (HR 5.356; 95% CI 1.301-22.052; P=0.020). Conclusions: Repeated measurements improved the predictive performance and revealed differences between FMD and EndoPAT RHI, which were better at predicting coronary events and heart failure, respectively.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.